Prostate cancer: Brachyury—a biomarker for progression and prognosis?


prostatectomy. Normal tissue showed no or low Brachyury expression, whereas high-grade prostatic intraepithelial neoplasia, primary prostate carcinoma and metastatic tissue demonstrated both cytoplasmic and nucleic Brachyury expression that increased with tumour malignancy and aggressiveness and was associated with Gleason score and TNM stage. A similar expression pattern (evaluated by semiquantitative reverse transcription PCR and western blotting) was recapitulated in cell lines representing different stages of prostate cancer progression. “Additionally, using available microarray datasets, we performed in silico analysis that extended and validated our findings in a large series of samples from across the globe,” notes Rui Reis, corresponding author on the study. “In a second approach, we modulated Brachyury levels in prostate cancer cell lines to understand its biological impact on prostate tumorigenesis. We demonstrated that the abrogation PROSTATE CANCER

DOI: 10.1038/nrurol.2014.184

Cite this paper

@article{Thoma2014ProstateCB, title={Prostate cancer: Brachyury—a biomarker for progression and prognosis?}, author={Clemens Thoma}, journal={Nature Reviews Urology}, year={2014}, volume={11}, pages={485-485} }